Title: Clinical and economic burden of lower respiratory tract infection due to respiratory syncytial virus in young children in Germany

Authors in order:

Caroline Beese[1] – Lead author

Lea Bayer[1] – corresponding author

Bennet Huebbe[1]

Jennifer Riedel[2]

Sima Melnik[2]

Gordon Brestrich[1]

Christof von Eiff[1]

Tobias Tenenbaum[3]

Affiliations:

[1] *Pfizer Pharma GmbH, Berlin, Germany*

[2] *Gesundheitsforen Leipzig GmbH, Leipzig, Germany*

[3] *Sana Klinikum Lichtenberg, Clinic for Child and Adolescent Medicine, Academic Teaching Hospital Charité-Universitätsmedizin Berlin, Germany*

Conflict of Interest Statements:

CB, LB, BH, and CvE are all employees of Pfizer in Germany, the sponsor of this study. SM and JR are employees of Gesundheitsforen Leipzig GmbH, paid by Pfizer to conduct the study. TT is an expert in the field of RSV and received an honorarium from Pfizer for input on the study design and review of the results.

Funding:

This study was sponsored by Pfizer.

ABSTRACT

Background: Clinical and economic burden of infections due to respiratory syntactical virus (RSV) in children <2 years of age in Germany is still underestimated.

Methods: In a retrospective health claims analysis, we identified RSV inpatient and outpatient episodes based on year-round specific RSV ICD-10 diagnoses or unspecified lower respiratory tract infection diagnoses during the RSV-season. High-risk groups were defined by ICD-10 codes. Hospitalization costs per patient were incurred between the beginning and end of an RSV episode. All-cause costs were compared to a matched control group without RSV infections based on age, sex, and prematurity in the inpatient and outpatient sectors.

Results The incidence of hospitalization due to RSV was substantially higher in infants (21/1,000) than in toddlers (5.4/1,000). Most hospitalizations occurred in the first six months of life; the highest hospitalization incidences were observed in the second month of life (46/1,000). Infants with risk factors had a 2.4 times higher risk for hospitalization than those without. The economic burden per episode was high in the first 3 months of life and especially for those with risk factors and/or prematurity. However, overall annual resource utilization for the healthcare system was higher for healthy children with no underlying risk factors than for those with risk factors.

Conclusion: RSV in children <2 years of age causes a considerable burden for the German healthcare system, both clinically and economically. Newborns, premature infants, children with chronic underlying risk factors are at highest risk for severe outcomes, but the overall disease burden affects healthy infants.

Word Count: 250

52 **Introduction**

53 Respiratory syncytial virus (RSV) is a leading cause of acute lower respiratory tract infections (acute LRTI)
54 and hospitalizations for acute LRTI in young children (1). In 2019 the global burden of RSV was estimated
55 to be 33 million episodes among children aged five years or younger, with 3.6 million hospitalizations,
56 26,300 RSV in-hospital deaths, and 101,400 RSV-attributable overall deaths (2). The majority of cases were
57 accounted for by children under one year of age. By the age of two years, most children have had an RSV
58 infection at least once (3). For industrialized countries, Li et al. (2022) also reported incidence rates for
59 RSV-associated acute lower respiratory infections at 38.5/1000 in children aged 1-12 months and
60 24.3/1000 in children younger than 5 years of age (2). Children with certain risk factors, such as
61 prematurity, congenital heart disease, or chronic lung disease, have an increased risk of RSV infections
62 with severe outcomes (4). In Germany, there are only very few studies that have described the clinical
63 burden of RSV in children, due to unspecific symptoms, limited standard-of-care testing and not least
64 because of the lack of nation-wide mandatory reporting of RSV. Reporting of confirmed RSV cases to the
65 Robert Koch Institute (RKI) became only recently mandatory in July 2023. Irrespective of mandatory
66 reporting, the Federal Health Monitoring System (in German: Das Informationssystem der
67 Gesundheitsberichterstattung des Bundes – GBE) makes inpatient data from the RKI, local ministries,
68 epidemiological registries, and secondary data from the German social insurance publicly available (5).
69 Therein, hospitalization cases are available by ICD-10 codes from the years 2000 to 2021, but no age
70 stratification below the age of 1 year is available. Furthermore, data from GBE cannot be stratified by risk
71 status for severe outcomes, preterm birth, months of life and calendar months. Furthermore, no data on
72 other health care resource utilization such as ICU admission and ventilatory support are available, as well
73 as length of hospitalization stay by risk status and prematurity are available.

74 The few studies that have described the clinical burden of RSV in children in Germany are either outdated
75 or focused on single centers in Germany – making general, nation-wide conclusions challenging. For
76 example, in a single-center study, the INSPIRE study, the authors reviewed medical records to identify RSV
77 cases in hospitalized children under five years of age between 2015 and 2018 (6). Although the INSPIRE
78 study showed for the first time that the highest number of RSV hospitalizations occurred in infants under
79 six months of life in Germany, the study only included children from a single center and did not report any
80 nation-wide or population-based incidence rates and did not provide more fine-grained estimates by e.g.,
81 months of life. Weigl et al. (2002) conducted a retrospective study on RSV cases in childhood that focused
82 on inpatients from the years 1996-2001 from two pediatric hospitals in the city of Kiel (7). A mean
83 incidence rate of 16/1000 was reported in children younger than 12 months. In comparison, data from
84 the GBE show a hospital incidence rate of RSV in infants (<12 months) from 2017-2019 of 24.1/1000 per
85 year (GBE-Bund, 5) – an increase of 50% within the last two decades. Given the limitations of the GBE data
86 with respect to granularity of the age and risk group stratification, more evidence is needed to better
87 understand the clinical burden of RSV in children in Germany.

88 In addition to the clinical burden, RSV infections pose a substantial economic burden to the healthcare
89 system. At the global level, a recent review reported average costs of €3,452.00 per inpatient episode and
90 €299 per outpatient episode among children under five years of age, summarizing data from Europe,
91 North America, and Australia between 1987 and 2017 (8). Ehlken et al. (9) examined inpatient and
92 outpatient costs for children under one year of age. Average inpatient costs of 2,601.00€ and average
93 outpatient costs of 68€ were reported. However, this study used data from 1999 to 2002, which may not
94 reflect the current economic burden of RSV.

95 To fill in the research gaps in the clinical and economic burden of RSV in children in Germany, we
96 conducted a retrospective study using health claims data to assess the hospitalization incidence rate,
97 mortality rate, and costs associated with RSV in children <2 years of age in Germany from 2014 to 2019,
98 covering the pre-Covid-19 pandemic years.

99 **Methods**

100 Study design and data source

101 The study retrospectively analyzed claims data from the German Statutory Health Insurance (SHI) system
102 using the German Analysis Database for Evaluation and Health Services Research (DADB), which is owned
103 by "Gesundheitsforen Leipzig GmbH". At the time of the data analyses, the DADB contained data on
104 approximately 4.1 million insured persons (5 % of the SHI population) and covered the period from 2013
105 to 2020. During the study period of 2014 to 2019, data from 3.9 million insured was available. Routinely
106 collected health claims data are provided by 16 statutory health insurers operating nationwide and
107 include patient characteristics, inpatient and outpatient diagnoses (International Classification of Diseases
108 10th revision codes, German modification (ICD-10-GM)) (10), drug prescriptions (Anatomical-Therapeutic-
109 Chemical classification system; ATC level 5 code), and cost information. Further information is available
110 on medical procedures (surgery and procedure keys; OPS), diagnosis-related groups (DRG) and incapacity
111 to work. The data provided by the cooperating health insurers is delivered annually, pseudo-/anonymized
112 and encrypted to prevent re-identification of individuals. The process of data collection and encryption
113 has been approved in Germany in accordance with national law. The information in the DADB has proven
114 to be a representative sample of the total German population. This is ensured by an annual comparison
115 with data from the Federal Social Insurance Office (11). The DADB has been successfully used in
116 submission to the German Health Technology Assessment authorities to describe patient demographics
117 in several indications as part of the benefit-risk assessment of medicines (12, 13, 14).

118 For the current study, claims data were selected from January 1, 2014, and December 31, 2019. The study
119 period was chosen to exclude the COVID-19 pandemic era to ensure results could be compared across the
120 study years and to exclude irregular RSV-seasons during and after the COVID-19 pandemic (15).

121 Study population

122 Data from children were included in the analyses if they: (1) were aged 1-24 months and were
123 observable for at least one year (365 days) and (2) had a diagnosis of RSV (ICD-10 codes: J12.1, J20.5,
124 J21.0, B97.4) or a diagnosis of unspecified bronchiolitis, bronchitis, pneumonia or acute lower
125 respiratory tract infections (UBP) based on ICD-10-GM codes (J20.8, J20.9, J21.8, J21.9, J18.0, J12.8,
126 J12.9, J18.8, J18.9, J22). Patients with UBP diagnoses were only included if the diagnosis occurred during
127 the respective RSV-season (Supplemental Table 1). according to Cai et al. (2022) (16). UBP diagnoses
128 were incorporated to increase the sensitivity of capturing RSV without substantial loss of specificity (17).
129 To be counted as a case, patients were required to have at least one principle or secondary RSV or UBP
130 inpatient diagnosis or one confirmed outpatient diagnosis. Patients who deceased during the study
131 period were included for the analysis of incidence and mortality rates but excluded from the cost
132 analysis. The study population was divided into two age groups: infants (1-12 months) and toddlers (13-
133 24 months). Since the exact date of birth is not available in DADB for data protection reasons, the age in
134 months was estimated based on the year of birth and the number of insured days in the calendar year;
135 hence all children were observable from birth. Consequently, infants ≤1 year (1-12 months) were fully
136 observable in the year of birth and toddlers were fully observable between >1 year and <2 years (13-24
137 months). Therefore, toddlers could only be included in data analysis from 2015 onwards, whereas
138 infants were included from 2014 onwards.

139 Definition of episode

140 The RSV population included in the analyses consisted of patients with RSV diagnoses in the reporting
141 years and/or UBP diagnoses during the RSV season and was reported separately for the outpatient and
142 inpatient healthcare sectors. Inpatient RSV/UBP cases without overnight stay in hospital have been
143 excluded.

144 For inpatient RSV episodes, the episode started on the date of the first RSV-related diagnosis with no
145 evidence of RSV 30 days before the first encounter of RSV (i.e., RSV index diagnosis). The episode start
146 date could be brought forward once if the admission date of an inpatient UBP diagnosis was up to 30 days
147 before the RSV index diagnosis. The length of an inpatient episode was extended to the date of a new RSV
148 or UBP inpatient diagnosis that occurred within 30 days of the previous diagnosis. For inpatient UBP
149 diagnoses to be included in RSV episode advancement or extension, the admission date of the UBP
150 diagnosis or RSV index diagnosis had to be within the RSV season. Even outside the RSV season, a diagnosis
151 of RSV could prolong RSV episodes. Consequently, inpatient RSV episodes were differentiated whether
152 they occurred with and without UBP diagnosis and UBP episodes were identified with only UBP diagnoses
153 within RSV season. For outpatient RSV episodes, an RSV episode started with the index diagnosis of
154 outpatient RSV or UBP and lasted until the end of the quarter year period in which the index diagnosis
155 was made. Outpatient UBP who had an inpatient RSV in the same quarter were excluded. Only outpatient
156 diagnoses of UBP could be combined with outpatient diagnoses of RSV and were used to distinguish
157 outpatient RSV episodes with and without UBP, and to define outpatient UBP episodes with only UBP
158 diagnosis codes. For patients with both inpatient and outpatient diagnoses of RSV (same for UBP) within
159 the same quarter, only inpatient diagnoses were considered.

160 Outcome measures

161 Study outcome measures included incidence rates, 90-day all-cause mortality rate, healthcare costs and
162 healthcare resource utilization. The number of cases in the database were extrapolated to the annual
163 birth cohorts published by the "Institute for Quality Assurance and Transparency in Healthcare" (IQTIG)
164 (18). Base populations were based on IQTIG monthly birth cohorts. Hospitalization incidence rates were
165 calculated as number of extrapolated cases divided by the mean population size at risk expressed as per
166 1,000 person-years and stratified by risk status (with or without preterm status or underlying medical risk
167 factor), month of life and calendar month. Due to low numbers of fatal cases, mortality rates could only
168 be computed across the entire study period from 2014-2019. The 90-day all-cause mortality rate was
169 calculated as the number of deceased patients within 90 days after an inpatient or outpatient RSV episode
170 divided by the total population size from 2014-2019. All-cause healthcare costs were calculated on a per
171 episode basis and for different time windows (30-days, 90-days, 365 days, 2-years). Costs included
172 inpatient, outpatient, and pharmacy costs separately. Healthcare resource utilization included hospital
173 length of stay (LOS), the number of ICU treatments, and level and corresponding costs of ventilation use.

174 Preterm status was defined as either prematurity or extreme prematurity based on the presence of ICD-
175 10 codes (P07.2 and P07.3). Risk status was defined as the presence of at least one risk factor based on
176 ICD-10 codes for prematurity, chronic cardiac disease, chronic respiratory disease, immunosuppression,
177 neurological disease, diabetes mellitus or a patient history of prophylactic immunotherapy (Supplemental
178 table 2) and was defined as a binary variable (yes/no).

179 Study population for cost analysis

180 RSV-attributable costs were analyzed as mean costs per episode and additionally as all cause excess costs
181 in comparison to a control group. To determine the excess costs for two years following an RSV episode,

182 a new patient population was identified, including only patients that had exactly one RSV episode within
183 the healthcare sector during the observation period of 2-years.

184 All-cause excess costs were determined by comparing the RSV population to a matched control group
185 based on month of life, sex, preterm status in a 1:4 matching ratio. The control group included patients
186 without an RSV diagnosis that could also be followed up for two years starting from the index date of the
187 matched RSV patient. Excess costs were defined as the difference between mean all-cause costs in the
188 RSV-cohort over a specific observation period and the mean all-cause costs in the control cohort over the
189 same observation period. Average annual economic burden was determined multiplying the extrapolated
190 mean annual hospitalization cases with the mean costs per episode for the respective risk and age group.
191 Mean all-cause cost values in the RSV population and the control group were compared using Mann-
192 Whitney-Wilcoxon test for continuous variables. When adjusting p-values for multiple comparisons, the
193 Benjamin-Hochberg procedure was used to limit the probability of false detections.
194

195 Ethical considerations: This study used aggregated and anonymized data, therefore not requiring approval
196 from Institutional Review Boards or Ethical Committees or informed consents from patients. The study
197 was conducted in accordance with legal and regulatory requirements and research practices described in
198 the "Good Epidemiological Practice guidelines issued by the International Epidemiological Association"
199 (19).

200 **Results**

201 Study population characteristics

202 Altogether, 15.7% of infants and 17.6% of toddlers in the database had risk factors and 6.1% of infants
203 and 6.2% of toddlers were born prematurely. Overall, in the database 3,834 inpatient RSV episodes were
204 identified in infants and 788 in toddlers. Correspondingly, among all inpatient episodes in infants, 30.6%
205 occurred in those with underlying risk factor and 13.1% in those born prematurely. Among RSV inpatient
206 episodes in toddlers, 38.8% occurred in those with at least one risk factor and 15.9% were born
207 prematurely.

208 **Clinical burden due to RSV**

209 Incidence rates by study year and preterm/risk status

210 Between 2015 and 2019, the total annual hospitalization incidence rate was higher in infants (21/1,000)
211 than in toddlers (5/1,000) (Table 1). Highest hospitalization incidence rates were observed in 2019 with
212 24/1,000 in infants and 7/1,000 in toddlers.

213 Compared to healthy infants, hospitalization incidence rates were 2.9 times higher in infants with extreme
214 prematurity, 2.6 with prematurity, and 2.4 in infants with at least one risk factor. Hospitalization incidence
215 rates were 8.3, 3.1 and 3.0 higher in toddlers with extreme and other preterm status and risk status
216 respectively in comparison to healthy toddlers. Hospitalization incidence rates across the study years were
217 highest for infants with extreme prematurity (Table 2).

218 Incidence rates by month of life and preterm/risk status

219 Most hospitalizations occurred during the first 6 months of life (61.4% of all cases in children <2 years of
220 age and 74.0% of cases in infants). The overall hospitalization incidence rate peaked at the age of 2 months
221 (hospitalization incidence rate across study years: 46/1,000). From age 3 months on, there was a gradual
222 decrease in the RSV incidences until age 13-24 months. A similar trend was observed among full-term

223 infants, with a peak hospitalization incidence rate noted in the age group of 2 months olds (44/1,000).
224 Among infants with any preterm status, the hospitalization incidence rate peaked at the age of 3 months
225 (85/1,000 across study years), initially decreasing sharply after the age of 3 months, and again after the
226 age of 7 months. Among infants with underlying risk factors, the hospitalization incidence rate peaked in
227 the age group of 1-month olds (77/1,000 across study years), followed by a decrease until 12 months
228 (Figure 1). Incidence rates in infants under 6 months were 2.9 times higher than in infants after 6 months
229 of age. Incidence rates in infants 1-3 months old were 1.4 times higher than infants 4-6 months old and
230 3.4 times higher than infants 7-12 months of age.

231 RSV mortality

232 Over the study period and within the analyzed data, 12 children died in the 90-days period following a
233 hospital admission. A total of 8 infants and 5 toddlers died; of the children that died, 7 were born pre-
234 maturely, while 6 were born at term. All children that died had at least one underlying risk factor. The
235 resulting calculated mortality rate was 0.005%.

236 **Economic burden and healthcare resource utilization related to RSV infections.**

237 Hospital length of stay (LOS) and number of hospitalizations

238 During the 30-days' time window, the median LOS was 5 days for both infants and toddlers. For infants
239 and toddlers with any preterm status median LOS was 6 days. Among infants with extreme prematurity
240 median LOS was 7 days and for those aged 1-3 months was 6 days. Over the maximum observation period
241 of two years, the mean number of all-cause hospitalizations increased from 1.07 (30-days period) to 1.66
242 (2-years period) in infants in the RSV-cohort and from 1.07 to 1.79 in toddlers during the respective
243 periods.

244 RSV-attributable cost and excess cost estimates

245 For the cost analysis, 3,376 hospitalized infants and 655 toddlers were identified. All-cause inpatient costs
246 in the RSV cohort were significantly higher than in the control group ($p < 0.001$) over all observation
247 periods (30, 90, 365 days, 2 years) and excess costs of RSV episodes increased with increasing observation
248 time (Table 3 and 4).

249 Mean costs per inpatient episode were high for all infants (€3,912), with higher costs associated with
250 younger age, preterm status, and risk status (Table 4). Mean inpatient episode costs were lower for
251 toddlers than for infants but remained high, with average costs of €3,510 per episode.

252 The 1-year mean excess costs for hospitalizations were similar in infants (€4,446) and toddlers (€4,570)
253 The mean excess costs per index year of an outpatient episode were €148 among all infants, and €277
254 among infants with an extreme prematurity status (ICD-10-GM: P07.2). Outpatient excess costs were
255 similar for infants and toddlers (index year excess costs infants: €148, toddlers: €179).

256 ICU stays and ventilation use.

257 Approximately 1% of hospitalized infants and <1% of hospitalized toddlers required ICU treatment. Most
258 infants that required ICU treatment during the 30-day period were diagnosed with bronchiolitis (72.7%),
259 followed by pneumonia (27.3%), and bronchitis (12.1%). Among hospitalized infants that received ICU
260 treatment, 7% required some form of ventilation use and <1% required mechanical ventilation. Due to
261 the higher overall proportion of hospitalizations occurring in full term infants, 84.8% of ICU admissions
262 occurred in infants born at term, and 51.5% in infants with an underlying risk factor or prematurity. Out
263 of all episodes in infancy that required ICU treatment, 57.6% of ICU admissions occurred in the first 3

264 months of life and 84,8% in the first 6 months of life. The mean costs per episode with ICU stay was
265 €19,181 among infants and €4,450 among toddlers. Costs of episodes that required mechanical
266 ventilation were especially high, with mean costs of 71,242 € (Table 5).

267 Annual economic burden

268 The overall annual economic inpatient burden of RSV in infants was an estimate of 61 million euros, with
269 56% (34 million euros) of the annual economic burden associated with care for infants born at term
270 without underlying risk factors and 44% (27 million euros) associated with care for infants with risk factors.
271 Care for all toddlers adds additional annual costs of 14 million (7,5 million in healthy toddlers, and 6,5
272 million in those with underlying risk factors), leading to annual costs of inpatient care for children < 2 years
273 of age of 75 million euros each year.

274 **Discussion**

275 In this retrospective cohort study using statutory health insurance data, we assessed the hospitalization
276 incidence rate, mortality, and costs associated with RSV in infants and toddlers in Germany from 2014-
277 2019. Our study presents recent, nation-wide, and population-based quantification of the RSV-burden in
278 young children in Germany, including data from 6 consecutive years right before the beginning of the
279 COVID-19 pandemic. Our study analyzed the hospitalization incidence rates by preterm/risk status and
280 months of life, as well as the distribution of RSV cases per calendar month. The highest hospitalization
281 incidence rate was observed in young infants aged 2 months, and the hospitalization incidence rate was
282 substantially higher in children with underlying risk factors including prematurity. Additionally, our study
283 demonstrated a considerable economic burden associated with RSV in Germany. Higher healthcare costs

284 were observed in young infants aged 1-3 months and children with a prematurity status. The highest costs
285 were associated with ICU treatment or mechanical ventilation.

286 Low age below 6 months of life has been recognized as a risk factor for RSV in earlier studies (4, 20), as
287 newborns have an immature immune system, and their small airways are especially affected by swelling
288 and mucous production due to the infection and inflammation. Our study confirms low age as a major risk
289 factor, with most hospitalizations occurring in the first six months of life and the highest incidence rates
290 were reported between the first and second month of life across other risk factors than prematurity.
291 Overall, our estimates – annual RSV hospitalization incidence rate of 21/1,000 in infants and 5/1,000 in
292 toddlers – are slightly lower but in reasonable proximity to other hospitalization incidence rates estimated
293 from European countries. Analyzing a nationwide database on RSV hospitalization cases, Jepsen (2018)
294 (21) estimated a hospitalization incidence rate of 29/1,000 for infants and 6.3/1,000 for toddlers between
295 2010 and 2015 in Denmark. Jepsen also found the highest incidence rates between the first and second
296 month of life, with a gradual decrease, thereafter, underlining the universal risk of RSV for newborns in
297 Europe. A similar age-related incidence pattern was observed for instance by Demont et al. (2021) (22) in
298 France. Our hospitalization incidences rates are also comparable to a recent US meta-analysis by
299 McLaughlin et al. (23), who reported hospitalization rates between 8.4 and 40.8 per 1,000, with a pooled
300 average of 19.4 in infants. Compared to estimates by Li (2021) (2) in industrialized countries, who
301 estimates a disease burden of 38/1,000, disease burden estimates in Germany remain relatively low. A
302 modelling study estimating RSV-associated hospitalizations in the European Union using time-series
303 estimates by Johannesen (2022) (24), also reported substantially higher RSV-associated hospitalization
304 incidence rates of 72.5 in children between 1-2 months old, 38.6 in children 3-6 months old and 17.5 per
305 1,000 in children aged 6-11 months for Germany (Del Riccio 2023) (25).

306 Hospitalization incidence rates were also notably higher in children with at least one underlying risk factor,
307 including premature birth. Prematurity has been widely acknowledged as a risk factor for severe outcomes
308 of RSV, globally (26, 27) and in Germany (4). Extreme prematurity in our study was associated with the
309 highest hospitalization incidence rates in infants. Notably, the influence of premature birth and other risk
310 factors on the risk for hospitalization seems to persist even in toddlers.

311 Like hospitalization incidence rates, associated inpatient costs and resource utilization underline the risk
312 for severe outcomes of RSV associated disease with the studied risk factors. Inpatient costs were higher
313 in the first months of life, and for those with preterm status and other underlying risk factors. This is in
314 line with other recent cost estimates from other European countries. For example, Kramer et al. (2018)
315 (28) reported similar mean costs per inpatient episode for infants born at term (3,437 €) and infants born
316 prematurely (6,324 €) in hospitals in Lyon, France. In addition, Kramer estimated higher costs for infants
317 aged <3 months (3,958 €) than infants >3 months old (3,234 €). Demont (2021) (22) also found the highest
318 costs in infants <3 months old. Overall, our cost estimates are comparable to inflation adjusted estimates
319 from Elhken's study in Germany. Taking the consumer price index from 2002 to 2019 for Germany into
320 account, the costs reported by Ehlken should have increased to 3,353€ for inpatients and 88€ for
321 outpatients. In addition, a recent study by Niekler et al. (2023) (29) estimated similar costs for
322 hospitalizations in infants (3,598€) in Germany. In terms of healthcare resource utilization, our study
323 compares to a single-center retrospective study in Germany, conducted by Hartmann, 2022 (6). Hartmann
324 estimated a similar median LOS of 5-days for children <6 months and higher median LOS in preterm infants
325 (7.5). Hartmann observed a high rate of ICU admissions for children between 1 and 6 months (9.3%) but
326 no ICU-admissions for children between 6-12 months, overall estimating slightly higher ICU-admissions
327 rates than our study (1% for infants).

328 While the relative risk for RSV hospitalization was higher for infants and toddlers with underlying risk
329 factors and preterm children, the highest overall clinical and economic burden was posed by healthy
330 children.

331 Limitations and Implications

332 It is important to mention that using health claims to analyze epidemiological and economic burden has
333 numerous strengths, but also several limitations. First, costs for outpatients are only available per
334 calendar year, thus outpatient costs could only be aggregated across the diagnosis year and not per
335 episode for all family insured persons. In addition, through health claims data, it is not possible to
336 determine whether an RSV-specific laboratory detection assay was positive prior to ICD-10 coding, as
337 virological confirmation is not a requirement, and the results of tests are not available in the health claims
338 data. However, RSV-codes (J12.1, J20.5, and J21.0) are usually allocated after laboratory-confirmed RSV
339 infection in the hospital setting (29). In the primary care setting, laboratory tests are not routinely
340 administered, thus identification of RSV-infections in the outpatient setting through health claims data
341 remains a significant challenge. Since there are no pathogen-specific treatment options in the primary
342 care setting for RSV, it is likely that RSV is not routinely diagnosed and therefore costs data from the
343 outpatient sector need to be interpreted with caution.

344 Conclusion

345 To our knowledge, this large observational study is the first to provide updated nation-wide, population-
346 based hospitalization incidence rates in Germany and the corresponding economic burden. In addition,
347 the study is the first to provide detailed epidemiological and economic estimates of the burden of disease
348 of LRTI-RSV infections by months of life, risk status and preterm status in Germany. Overall, our study

349 shows a substantial clinical burden among young children with RSV infections in Germany. Both, newborns
350 and children with a preterm status or a risk medical factor show an elevated and substantial risk of severe
351 RSV infections, although according to our analyses most children who were hospitalized did not offer any
352 risk factors prior to hospitalization. Also economically, RSV infections in young children pose a significant
353 burden on the German healthcare systems. Our study identifies the most vulnerable demographics and
354 shows that the overall disease burden remains high in young, healthy infants, emphasizing the need for
355 broad protection already at birth.

356 Acknowledgements: Medical writing support was provided by Qi Yan, PhD, MS (Pfizer, Inc). We thank
357 Julia Schiffner-Rohe for valuable discussions throughout the study process.

358

359 References:

360 1 Coultas, J. A., Smyth, R. & Openshaw, P. J. (2019). Respiratory syncytial virus (RSV). A scourge from
361 infancy to old age. *Thorax* **74,** 986–993; 10.1136/thoraxjnl-2018-212212.
362
363 2 Li, Y., Wang, X., Blau, D. M., Caballero, M. T., Feikin, D. R., Gill, C. J., ... & Nair, H. (2022). Global,
364 regional, and national disease burden estimates of acute lower respiratory infections due to respiratory
365 syncytial virus in children younger than 5 years in 2019: a systematic analysis. The Lancet, 399(10340),
366 2047-2064.
367
368 3 Barr, R., Green, C.A., Sande, C.J., Drysdale, S.B. (2019). "Respiratory syncytial virus: diagnosis,
369 prevention and management." Ther Adv Infect Dis 6: 2049936119865798.
370
371 4 Cai, W., Buda, S., Schuler, E., Hirve, S., Zhang, W., Haas, W. (2020). "Risk factors for hospitalized
372 respiratory syncytial virus disease and its severe outcomes." Influenza Other Respir Viruses 14(6): 658-
373 670.
374
375 5 Federal Health Monitoring System: The Information System of the Federal Health Monitoring. 2015.
376 The Federal Health Monitoring System (gbe-bund.de)
377
378 6 Hartmann, K., Liese, J.G., Kemmling, D., Prifert, C., Weißbrich, B., Thilakarathne, P., Diels, J., Weber, K.,
379 Streng, A. (2022). "Clinical Burden of Respiratory Syncytial Virus in Hospitalized Children Aged ≤5 Years
380 (INSPIRE Study) " The Journal of Infectious Diseases 226(3): 386-395.
381
382 7 Weigl, J. A. I., Puppe, W., Rockahr, S., & Schmitt, H. J. (2002). *Burden of disease in hospitalized RSV-*
383 *positive children in Germany*. Klinische Pädiatrie, 214(06), 334-342.
384
385 8 Zhang, S., Akmar, L. Z., Bailey, F., Rath, B. A., Alchikh, M., Schweiger, B., ... & Nair, H. (2020). Cost of
386 respiratory syncytial virus-associated acute lower respiratory infection management in young children at
387 the regional and global level: a systematic review and meta-analysis. The Journal of infectious diseases,
388 222(Supplement_7), S680-S687.
389
390 9 Ehlken, B., Ihorst, G., Lippert, B., Rohwedder, A., Petersen, G., Schumacher, M., ... & PRIDE Study
391 Group. (2005). *Economic impact of community-acquired and nosocomial lower respiratory tract*
392 *infections in young children in Germany*. European journal of pediatrics, 164, 607-615.
393
394 10 Federal Institute for Drugs and Medical Devices (BfArM). *ICD-10-GM: International Statistical*
395 *Classification of Diseases, German Modification*. 2022. https://www.bfarm.de/EN/Code-
396 systems/Classifications/ICD/ICD-10-GM/_ node.html
397

11 Bundesamt für soziale Sicherung [Federal Office for Social Security]. *Data Compilations and Evaluations*. https://www.bundesamtsozialesicherung.de/de/themen/risikostrukturausgleich/datenzusammenstellungen-und-auswertungen/

12 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen [Institute for Quality and Efficiency in Health Care]. *Ceftolozan/Tazobactam (akute Pyelonephritis) – Nutzenbewertung gemäß § 35a SGB V* [Ceftolozane/tazobactam (acute pyelonephritis) – benefit assessment according to Section 35a SGB V]. https://www.g-ba.de/downloads/92-975-3622/2020-03-15_Nutzenbewertung-IQWiG_Ceftolozan-Tazobactam_D-526.pdf.

13 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen [Institute for Quality and Efficiency in Health Care]. *Cenobamat (Epilepsie) – Nutzenbewertung gemäß § 35a SGB V* [Cenobamate (epilepsy) – benefit assessment according to § 35a SGB V]. https://www.g-ba.de/downloads/92-975-4768/2021-06-01_Nutzenbewertung-IQWiG_ Cenobamat_D-694.pdf.

14 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen [Institute for Quality and Efficiency in Health Care]. *Ozanimod (Colitis ulcerosa) – Nutzenbewertung gemäß § 35a SGB V* [Ozanimod (ulcerative colitis) – benefit assessment according to § 35a SGB V]. https://www.g-ba.de/downloads/92-975-5352/2021-12-15_ Nutzenbewertung-IQWiG_Ozanimod_D-769.pdf

15 Kiefer, A., Pemmerl, S., Kabesch, M., & Ambrosch, A. (2023). Comparative analysis of RSV-related hospitalisations in children and adults over a 7 year-period before, during and after the COVID-19 pandemic. *Journal of Clinical Virology*, *166*, 105530.

16 Cai, W., Dürrwald, R., Biere, B., Schweiger, B., Haas, W., Wolff, T., ... & Reiche, J. (2022). Determination of respiratory syncytial virus epidemic seasons by using 95% confidence interval of positivity rates, 2011–2021, Germany. *Influenza and Other Respiratory Viruses*, *16*(5), 854-857.

17 Cai, W., Tolksdorf, K, Hirve, S., Schuler, E., Zhang, W., Haas, W., Buda, S. (2020). "Evaluation of using ICD-10 code data for respiratory syncytial virus surveillance." Influenza Other Respir Viruses 14(6): 630-637.

18 Institut für Qualitätssicherung und Transparenz im Gesundheitswesen. Bundesauswertungen. https://iqtig.org/veroeffentlichungen/bundesauswertung/

19 Good Epidemiological Practice. Guidelines for Proper Conduct of Epidemiological Research, (2007)

20 Hall, C. B., Weinberg, G.A., Iwane, M.K., Blumkin, A.K., Edwards, K.M., Staat, M.A., Auinger, P., Griffin, M.R., Poehling, K.A., Erdman, D., Grijalva, C.G., Zhu, Y., Szilagyi, P. (2009). "The Burden of Respiratory Syncytial Virus Infection in Young Children." New England Journal of Medicine 360(6): 588-598.

21 Jepsen, M. T., Trebbien, R., Emborg, H.D., Kause, T.G., Schonning, K., Voldstedlund, M. Nielsen, J., Fischer, T.K. (2018). "Incidence and seasonality of respiratory syncytial virus hospitalisations in young children in Denmark, 2010 to 2015." Euro Surveill 23(3).

22 Demont, C., Petrica, N., Bardoulat, I., Duret, S., Watier, L., Chosidow, A., ... & Lemaitre, M. (2021). Economic and disease burden of RSV-associated hospitalizations in young children in France, from 2010 through 2018. *BMC infectious diseases, 21(1), 730. ISO 690*

23 McLaughlin, J. M., Khan, F., Schmitt, H.J., Agosti, Y., Jodar, L., Simoes, E.A.F., Swerdlow, D.L. (2022). "Respiratory Syncytial Virus-Associated Hospitalization Rates among US Infants: A Systematic Review and Meta-Analysis." J Infect Dis 225(6): 1100-1111.

24 Johannesen, C. K., Wijhe, M.v., Tong, S., Fernandez, L.V., Heikkinen, T., van Boven, M., Wang, X., Boas, H., Li, Y., Campbell, H., Paget, J., Stona, L., Teirlinck, A., Lehtonen, T., HNohynek, H., Bangert, M., Fischer, T.K. (2022). "Age-Specific Estimates of Respiratory Syncytial Virus-Associated Hospitalizations in 6 European Countries: A Time Series Analysis." The Journal of Infectious Diseases 226(Supplement_1): S29-S37.

25 Del Riccio, M., Spreeuwenberg, P., Osei-Yeboah, R., Johannesen, C. K., Vazquez Fernandez, L., Teirlinck, A. C., ... & Paget, J. (2023). Defining the Burden of Disease of RSV in the European Union: estimates of RSV-associated hospitalisations in children under 5 years of age. A systematic review and modelling study. The Journal of infectious diseases, jiad188.

26 Hall, C. B., Weinberg, G. A., Iwane, M. K., Blumkin, A. K., Edwards, K. M., Staat, M. A., ... & Szilagyi, P. (2009). The burden of respiratory syncytial virus infection in young children. New England Journal of Medicine, 360(6), 588-598.

27 Welliver, R. C. (2003). "Review of epidemiology and clinical risk factors for severe respiratory syncytial virus (RSV) infection." J Pediatr 143(5 Suppl): S112-117.

28 Kramer, R., Duclos, A., Lina, B., Casalegno, J.S. (2018). "Cost and burden of RSV related hospitalisation from 2012 to 2017 in the first year of life in Lyon, France." Vaccine 36(45): 6591-6593.

29 Niekler, P., Goettler, D., Liese, J. G., & Streng, A. (2023). Hospitalizations due to respiratory syncytial virus (RSV) infections in Germany: a nationwide clinical and direct cost data analysis (2010–2019). Infection, 1-10.

477 Table 1: RSV Hospitalization Incidence Rates per Calendar Year and per 1,000 Person-Years and Extrapolated Number of Cases per Calendar

478 Year by different age groups between 2014-2019

Month of life	**2014**		**2015**		**2016**		**2017**		**2018**		**2019**		**2014-19**	
	IR	Cases	IR	Cases	IR	Cases	IR	Cases	IR	Cases	IR	Cases	IR	Cases
1-3	30.9	5,315	32.5	5,783	33.9	6,534	41.0	7,940	34.9	6,679	42.1	8,041	36.0	40,293
4-6	23.9	4,114	23.1	4,118	26.9	5,188	27,8	5,376	21.4	4,1	29.0	5,538	25.4	28,440
7-12	10.7	3,668	10.1	3,609	10.0	3,866	10.2	3,932	11.8	4,502	11.7	4,451	10.7	24,029
1-6	27.4	9,429	27.8	9,901	30.4	11,722	34.4	13,316	29.2	10,785	35.6	13,579	30.7	68,733
1-12	19.5	13,098	19.3	13,509	20.9	15,589	22.3	17,249	19.8	15,288	23.7	18,031	21.0	92,762
13-24	n.a.	n.a.	4.4	2,939	5.6	3,944	4.8	3,582	5.0	3,842	7.2	5,535	5.4	19,842
1-24	n.a.	n.a.	12.0	16,401	13.4	19,338	13.7	20,831	12.3	19,078	15.3	23,514	13.9	112,260

479

480

481 Tables 2: Hospitalization Incidence Rates 2014-2019 by Risk and Preterm Status a

	Infants				Toddlers			
	Healthy	P07.2	P07.3	Any Risk Status	Healthy	P07.2	P07.3	Any Risk Status
Incidence	17.3	49.85	44.36	40.82	4.0	33.4	12.3	11.9
Cases (Average)	10,743	149	1,866	4,718	2,430	106	525	1,538

482 *Note. ICD-10 GM Code P07.2 denotes newborn children with extreme prematurity, born before the 29th gestational week. ICD-10 code-GM Code*
483 *P07.3 denotes other preterm infants, infants born between after the 29th and before the 38th gestational week. Any risk status denotes children*
484 *with at least one risk factor including preterm status.*

485

Table 3: Healthcare Resource Utilization per Age, Risk- and Preterm Status Infants (2014 – 2019)

	30-days Median LOS	Episode costs (SD)	30-days excess costs	90-days excess costs	365-days excess costs	2-years excess costs	Outpatient excess costs (index year)
1-12 months	5	3,912.12 (7,798,59)	3,534.34€	3,879.27 €	4,446.66€	4,904.20 €	147.97 €
1-3 months	6	4,651.57 (10,454.58)	4,011.95€	4,275.12 €	4,517.76€	4,573.33 €	74.46 €
4-6 months	5	3,336.80 (5,083.86)	3,143.92€	3,440.26 €	3,832.44€	4,144.34 €	116.73 €
7-12 months	5	3,295.86 (3,904.64)	3,160.16€	3,715.43 €	5,095.86€	6,469.43 €	188.10 €
Full Term	5	3,6114,05 (6,980.16)	3,437.35€	3,792.42 €	4,405.96€	4,902.73 €	154.10 €
Any preterm status	6	5,932.67 (11,765.05)	4,191.80€	4,467.98 €	4,725.14€	4,914.19 €	91.46 €
Any risk status	6	5,660.17 (12,178.81)	4,683.75€	5,501.65 €	6,305.00€	6,765.87 €	273.61 €
P07.2	7	14,089.85 (27,316.03)	4,737.28€	5,813.57 €	5,400.17€	4,488.38 €	277.47 €
P07.3	6	5,391.52 (9,752.89)	4,155.61€	4,378.72 €	4,680.36€	4,942.43 €	77.55 €

Note. ICD-10 GM Code P07.2 denotes newborn children with extreme prematurity, born before the 29th gestational week. ICD-10 code-GM Code P07.3 denotes other preterm infants, infants born between after the 29th and before the 38th gestational week. Risk status denotes children with at least one risk factor including preterm status. Any preterm status denotes children with ICD-10 code P07.2 or P07.3.

491 Table 4: Healthcare Resource Utilization per Age, Risk- and Preterm Status Toddlers (2014 – 2019)

	30-days Median LOS	Episode costs (SD)	30-days excess costs	90-days excess costs	365-days excess costs	2-years excess costs	Outpatient excess costs (index year)
13-24 months	5	3,510.36 € (5,432.86)	3,371.51€	3,756.39 €	4,570.32€	5,211.34 €	179,40 €
Full Term	5	3,377.67 € (5,475.18)	3,259.34 €	3,508.09 €	4,046.48 €	4,403.92 €	769.15 €
Any preterm status	5	3,337.67 € (5,475.18)	3,259.34€	5,057.01 €	7,314.23 €	9,440.71 €	198,32 €
Any risk status	6	4,205.40 € (5,175.14)	3,959.09€	4,680.73 €	6,235.87 €	7,680.11 €	250,29 €
P07.2	7	4,828.43 € (2,853.82)	4,627.00€	4,750.16 €	6,161.71€	8,101.28 €	604,87 €
P07.3	7	4,207.45 € (8,619.14)	3,868.94€	5,120.49 €	7,552.68 €	9,717.83 €	167,05 €

492

493 *Note. ICD-10 GM Code P07.2 denotes newborn children with extreme prematurity, born before the 29th gestational week. ICD-10 code-GM Code*
494 *P07.3 denotes other preterm infants, infants born between after the 29th and before the 38th gestational week. Risk status denotes children with*
495 *at least one risk factor including preterm status. Any preterm status denotes children with ICD-10 code P07.2 or P07.3.*

496

497 Table 5: Percent of utilization of respiratory support and associated costs in infants by support level

Ventilation Level	%	Cost
No respiratory support	93%	3,130.18 €
Oxygen therapy	2%	6,682.28 €
Non- invasive ventilatory support	2%	6,689.71 €
Noninvasive ventilation	2%	15,636.61 €
Invasive mechanical ventilation	1%	71,242.12 €

498 *Note. Ventilation level was assessed based on OPS codes. Oxygen therapy (OPS 8-720).: noninvasive ventilatory support (OPS 8-711.4x), non-*

499 *invasive ventilation (OPS 8-712.0), invasive mechanical ventilation (OPS 8-711.1x)*

500

501 Figure 1: Hospital Incidence Rate per cross stratified by months of life and preterm status, risk status 2014-2019



502

503 *Note. Risk status includes prematurity status.*